



FOR IMMEDIATE RELEASE

May 4, 2009

Methapharm Inc. announces Canadian Distribution of Erythrocin[®] (erythromycin lactobionate injection)

Amdipharm International Ltd. (Amdipharm) announced today that Methapharm Inc. will assume the role of distributor of the Erythrocin[®] (erythromycin lactobionate injection) 500 mg and 1 g products in Canada. Erythrocin[®] IV is a long established antibiotic used in the treatment of patients when oral administration is not possible or when it is desirable to obtain higher serum levels of erythromycin than achievable with orally administered preparations.

Methapharm will begin distributing Erythrocin IV effective today.

About Methapharm Inc.

Methapharm, headquartered in Brantford, Ontario is a privately held, full-service pharmaceutical distribution company offering sales and marketing, regulatory services, market access, and distribution capabilities for product partnership opportunities. Operating in the United States and Canada, we are focused on the commercialization and marketing of niche pharmaceutical products and related medical devices in either country.

About Amdipharm International Ltd.

Amdipharm is division of Waymade International Holdings Limited a global pharmaceutical business. Amdipharm was formed in 2002 with the aim of making essential prescription medicines available to meet real clinical need but which may no longer be a priority for research based pharmaceutical companies. Amdipharm specializes in marketing internationally branded products to primary and secondary care prescribers.

For more information:

Chris Calenti
General Manager
Methapharm Inc.
Tel: (+1) 519.751.3602

Simon Tucker
International Business Manager
Amdipharm Sales and Marketing Ltd.
Tel: (+1) 305.865.8302

[®] Erythrocin is a registered Trade-Mark of Amdipharm International Ltd.